[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Weinreb I, Perez-Ordoñez B: Non-small cell neuroendocrine carcinoma of the sinonasal tract and nasopharynx. Report of 2 cases and review of the literature. Head Neck Pathol; 2007 Sep;1(1):21-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first had a tumor involving left ethmoid sinus and nasal cavity and the second, a neoplasm involving nasopharynx, sphenoid sinus, with bilateral involvement of cavernous sinuses.
  • The second is alive with locally advanced disease 7 years after radiotherapy and chemotherapy.
  • Other cases do not show specific features and are probably best regarded as "neuroendocrine carcinoma, NOS".
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Nasal Cavity / pathology. Nasopharyngeal Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Paranasal Sinuses / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1995 Jul;27(1):79-82 [7557912.001]
  • [Cites] Hum Pathol. 1998 Aug;29(8):826-32 [9712424.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2567-73 [15517582.001]
  • [Cites] Neurosurg Focus. 2002 May 15;12(5):e3 [16119901.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):299-306 [16163447.001]
  • [Cites] Pathol Res Pract. 1984 Jul;178(6):562-9 [6091074.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1617-22 [11037813.001]
  • [Cites] Rhinology. 2001 Mar;39(1):52-4 [11340699.001]
  • [Cites] Cancer. 1980 Jan 15;45(2):330-9 [6243246.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2388-405 [7139532.001]
  • [Cites] Mod Pathol. 1995 May;8(4):421-6 [7567943.001]
  • (PMID = 20614276.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807510
  • [Keywords] NOTNLM ; Carcinoid tumor / Nasal cavity / Neuroendocrine carcinoma / Olfactory neuroblastoma / Paranasal sinuses / Small cell carcinoma
  •  go-up   go-down


2. Chamberlain MC: Treatment of intracranial metastatic esthesioneuroblastoma. Cancer; 2002 Jul 15;95(2):243-8
Genetic Alliance. consumer health - Esthesioneuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of intracranial metastatic esthesioneuroblastoma.
  • BACKGROUND: Esthesioneuroblastoma (ENB) is an uncommon tumor that may metastasize to the central nervous system (CNS).
  • To the authors' knowledge there is no current consensus regarding treatment.
  • The current study was conducted to determine the toxicity and response rate of combined modality therapy in the treatment of patients with ENB metastatic to the brain.
  • CNS-directed therapy included radiotherapy (to the brain in three patients and to the spine in two patients) and chemotherapy (systemic in six patients and regional in three patients).
  • Systemic chemotherapy was comprised of carboplatin, lomustine, and vincristine administered every 2 months.
  • RESULTS: Between 1-6 cycles of systemic chemotherapy were administered (median, 4.5 cycles).
  • and 6-19 cycles of regional chemotherapy were administered (median, 17 cycles).
  • No treatment-related deaths were reported.
  • CONCLUSIONS: In the small cohort of patients in the current study, combined modality therapy was found to have modest toxicity and palliative efficacy.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Central Nervous System Neoplasms / therapy. Esthesioneuroblastoma, Olfactory / pathology. Esthesioneuroblastoma, Olfactory / secondary. Esthesioneuroblastoma, Olfactory / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Ethmoid Sinus. Female. Humans. Male. Middle Aged. Nasal Cavity. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10679
  • (PMID = 12124822.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Gabriele AM, Airoldi M, Garzaro M, Zeverino M, Amerio S, Condello C, Trotti AB: Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy. Tumori; 2008 May-Jun;94(3):320-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS AND BACKGROUND: To report the dosimetric data and clinical outcomes of patients with advanced neoplasm of the paranasal sinuses and nasal cavity, treated by three-dimensional conformal radiotherapy.
  • The primary tumor was located as follows: maxillary sinus 15 (48.4%); ethmoid sinus 10 (32.3%); nasal cavity 6 (19.3%).
  • The patients were separated in two groups according to the modality of treatment: group A included 21 patients treated with postoperative three-dimensional conformal radiotherapy with or without chemotherapy; group B included 10 patients treated with radical three-dimensional conformal radiotherapy with or without chemotherapy.
  • The median radiation dose to the planning target volume was 60 Gy (range, 56-63) for patients who underwent complete surgical resection and 68 Gy (range, 64-70) for those who did not have tumor resection or patients with residual disease.
  • Five-year local tumor control and overall survival actuarial rates were 74% and 72%, respectively, in the postoperative setting, 20% and 25%, respectively, with the primary radiotherapy.
  • No patient developed radio-induced blindness; 4 patients underwent enucleation as part of radical surgery.
  • The prognosis depends on localization, tumor stage and treatment modality.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / pathology. Nose Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Ethmoid Sinus. Female. Follow-Up Studies. Humans. Male. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / radiotherapy. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705398.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Mikami Y, Tsukuda M, Kawai S, Kagesato Y, Tanigaki Y, Horiuchi C, Mochimatsu I: [Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1]. Gan To Kagaku Ryoho; 2003 Oct;30(10):1473-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1].
  • Case 1, a 52-year-old man was admitted to our department a diagnosis of supraglottic laryngeal cancer (T3N2cM0) on January 25, 2000.
  • Concurrent chemoradiotherapy consisting of 2 courses of chemotherapy and radiation therapy at 70.2 Gy was administered.
  • After the treatment, a biopsy showed a remaining cancer in the primary lesion.
  • Case 2 was a patient with highly-differentiated adenocarcinoma in the ethmoid sinus (T3N2bM0).
  • The patient was inoperable and was given radiation therapy of 64.8 Gy.
  • Because of no change of the tumor after radiotherapy, TS-1 was administered at 60 mg x 2/day for 4 weeks followed by a 2-week rest.
  • After TS-1 was administered for 3 courses, a CT showed a remarkable regression of the tumor resulting in a PR for the primary and the neck lesion.
  • The ulcer was an adverse reaction of grade 3, which was improved by conservative therapy.
  • No clear tumor has been observed, and the clinical outcome is considered to be a CR.
  • TS-1 is considered to be an excellent oral anticancer drug in terms of its anti-tumor effect and the patient's QOL.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Head and Neck Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Drug Administration Schedule. Drug Combinations. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Quality of Life. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14584280.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


5. Wang J, Sun NC, Weinstein SM, Canalis R: Primary T-cell-rich B-cell lymphoma of the ethmoid sinus. A case report with 5 years of follow-up. Arch Pathol Lab Med; 2000 Aug;124(8):1213-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary T-cell-rich B-cell lymphoma of the ethmoid sinus. A case report with 5 years of follow-up.
  • Accurate diagnosis and proper treatment are essential to assure a favorable prognosis.
  • To our knowledge, this is the first report of ethmoid sinus presentation of TCRBCL in an Epstein-Barr virus-negative 51-year-old man.
  • Combined chemotherapy and radiotherapy were administered based on the correct diagnosis.
  • [MeSH-major] Ethmoid Sinus / pathology. Lymphoma, B-Cell / pathology. Paranasal Sinus Neoplasms / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Antigens, CD / biosynthesis. Biomarkers, Tumor / biosynthesis. Biopsy. Combined Modality Therapy. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10923086.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantù G, Pierotti MA, Pilotti S: Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol; 2004 Dec 15;22(24):4901-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
  • PURPOSE: To assess the role of TP53 status in predicting pathologic complete remission after primary chemotherapy in patients with ethmoidal intestinal-type adenocarcinoma (ITAC).
  • PATIENTS AND METHODS: Thirty patients with ethmoidal ITAC enrolled onto a phase II study received chemotherapy with cisplatin, fluorouracil, and leucovorin (PFL) followed by surgery and radiation.
  • On surgical specimens, absence of viable tumor cells was defined as pathologic complete remission (pCR).
  • In patients with wild-type (wt) TP53 or functional p53 protein, the pCRs were 83% and 80%, respectively; in patients with mutated TP53 or impaired p53 protein, pCRs were 11% and 0%, respectively (P < or = .0001).
  • CONCLUSION: The results indicate the existence of two genetic ITAC subgroups, defined by differences in TP53 mutational status or protein functionality, that strongly influence pathologic response to primary chemotherapy and, ultimately, prognosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ethmoid Sinus / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / genetics. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. DNA Mutational Analysis. Female. Fluorouracil / administration & dosage. Forecasting. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prospective Studies. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611505.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Abrahão M, Gonçalves AP, Yamashita R, Dedivitis RA, Santos RO, Nascimento LA, Mudo ML, Ferraz FA, Cervantes O: Frontal sinus adenocarcinoma. Sao Paulo Med J; 2000 Jul 6;118(4):118-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontal sinus adenocarcinoma.
  • CONTEXT: Paranasal sinus cancer is considered rare, with an incidence of less than 1 per 100,000 per year, with the frontal sinus being the primary site in only 0.3%.
  • We report a case of adenocarcinoma arising in the frontal sinus.
  • CT scan showed a soft-tissue mass involving frontal sinus with intracranial invasion through the posterior wall.
  • The anterior ethmoid sinus and the medial aspect of the right orbit were also involved.
  • She underwent an en-bloc tumor resection by craniotomy including orbital clearance.
  • After surgery she had tumor recurrence, and chemotherapy and radiotherapy were started resulting in partial improvement.
  • [MeSH-major] Adenocarcinoma / diagnosis. Frontal Sinus. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10887389.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] BRAZIL
  •  go-up   go-down


8. de Tella OI Jr, Silva LR, Stavale JN, Herculano MA, de Paiva Neto MA, Agner C: Aggressive intracranial fibromatosis: case report. Arq Neuropsiquiatr; 2006 Jun;64(2B):516-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracranial fibromatosis is extremely rare and requires aggressive treatment to prevent recurrence.
  • The lesion extended through the sphenoid, ethmoid sinus and nasal cavity, destroying the right roof of the orbit and penetrating in anterior skull base.
  • A combined anterior craniofacial approach was performed; complete resection with surgical margin was impossible due to the localization of the tumor and relation to important neurovascular structures.
  • Radiotherapy and chemotherapy are often required to improve local control of the lesion.
  • [MeSH-major] Brain Neoplasms / diagnosis. Fibromatosis, Aggressive / diagnosis
  • [MeSH-minor] Adult. Craniotomy / methods. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / surgery. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • Genetic Alliance. consumer health - Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917630.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


9. Kohanawa R, Tabuchi K, Okubo H, Nagata M, Hara A: Primary osteogenic sarcoma of the ethmoid sinus: a case report. Auris Nasus Larynx; 2005 Dec;32(4):411-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteogenic sarcoma of the ethmoid sinus: a case report.
  • Primary osteogenic sarcoma arising from the ethmoid sinus is an extremely rare condition.
  • Computed tomography (CT) scan showed tumor calcification, which is a common feature of osteogenic sarcoma.
  • Exploratory ethmoidectomy was performed, and histological examination confirmed the diagnosis of osteogenic sarcoma.
  • Radiation therapy and chemotherapy failed to reduce the tumor size.
  • Although primary osteogenic sarcoma of the ethmoid sinus is uncommon, the authors emphasize that osteogenic sarcoma should be suspected when tumor calcification was observed on CT scan and that adequate surgical resection with negative surgical margins remains the mainstay of treatment of this lesion.
  • [MeSH-major] Ethmoid Bone / pathology. Ethmoid Sinus / pathology. Osteosarcoma / secondary. Paranasal Sinus Neoplasms / pathology. Skull Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / radiography. Neoplasms, Second Primary / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039814.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


10. Kajikawa H, Chatani M, Matsushiro N, Kamakura T, Kitamura T, Okumura S: [A case of advanced adenocarcinoma of the ethmoid sinus treated by chemoradiation with S-1]. Gan To Kagaku Ryoho; 2009 May;36(5):871-3
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced adenocarcinoma of the ethmoid sinus treated by chemoradiation with S-1].
  • We report a case of advanced adenocarcinoma in the left ethmoid sinus invading the frontal sinus, the frontal skull base and the orbits(T4bN0M0 and Stage IVB).
  • With the goal of functional preservation, we carried out radiation therapy with total 60 Gy irradiation and chemotherapy with S-1 80 mg/body/day before a radical operation.
  • The tumor clinically disappeared without surgical treatment, and there was no sign of recurrence for 2.5 years.
  • When we decide the treatment policy for advanced adenocarcinoma of the ethmoid sinus, chemoradiotherapy wit S-1 might be one of the effective treatments before radical operation to control the disease with preservation of functions.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ethmoid Sinus. Nose Neoplasms / drug therapy. Nose Neoplasms / radiotherapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Combined Modality Therapy. Drug Combinations. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461198.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


11. Lee O, Cromwell LD, Weider DJ: Carcinomatous meningitis arising from primary nasopharyngeal carcinoma. Am J Otolaryngol; 2005 May-Jun;26(3):193-7
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was subsequently diagnosed with nasopharyngeal carcinoma by biopsy and treated with radiation as well as chemotherapy.
  • In 1993, magnetic resonance imaging scan of the head revealed recurrence of nasopharyngeal carcinoma with involvement of the ethmoid sinuses as well as extension of the tumor into the frontotemporal leptomeninges.
  • We also review the literature with respect to the diagnosis and treatment of carcinomatosis meningitis.
  • [MeSH-minor] Adult. Ethmoid Sinus / pathology. Facial Paralysis / etiology. Fatal Outcome. Female. Gadolinium. Humans. Magnetic Resonance Imaging. Meningitis / etiology. Otitis Media with Effusion / etiology. Radiographic Image Enhancement. Radioisotopes. Recurrence

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858776.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioisotopes; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


12. Park KJ, Kang SH, Lee HG, Chung YG: Olfactory neuroblastoma following treatment for pituitary adenoma. J Neurooncol; 2008 Nov;90(2):237-41
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma following treatment for pituitary adenoma.
  • Olfactory neuroblastoma is extremely rare as a second neoplasm.
  • We report an unusual case of olfactory neuroblastoma in a 59-year-old woman who had undergone two operations and received 54 Gy of irradiation for pituitary adenoma 20 years ago.
  • At the time of admission, the patient presented with nasal obstruction and frequent epistaxis.
  • Imaging studies showed a large mass in the nasal cavities and ethmoid sinus, extending to the intracranial area, with no evidence of any recurrence of the previous pituitary adenoma.
  • The tumor was completely excised via a trans-cranial and trans-nasal approach.
  • A diagnosis of olfactory neuroblastoma was established, and the patient was given postoperative chemotherapy.
  • Although relatively uncommon, second neoplasms are an important consideration in the differential diagnosis of patients with new or recurring symptoms after treatment for pituitary adenoma.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3567-72 [12915637.001]
  • [Cites] Oncology. 1990;47(2):199-205 [1969134.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] Arch Pathol. 1972 Jan;93(1):26-31 [5006996.001]
  • [Cites] Neurosurg Focus. 2007;23(3):E7 [17961019.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] J Neurosurg. 1981 Oct;55(4):615-9 [7277008.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):172-8 [9442520.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):230-9 [17047388.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Oct-Nov;18(7):459-63 [11594709.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Nov;55(5):613-6 [11894972.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:69-74 [7841081.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):502-12 [2204689.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):949-55 [1431959.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Neurochirurgia (Stuttg). 1993 Nov;36(6):203-6 [8309496.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):28-31 [8315464.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):854-60 [17599761.001]
  • (PMID = 18679581.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Uysal KM, Koyuncuoğlu M, Akman F, Güneri A, Sarialioğlu F, Kargi A, Olgun N, Manisali M: A rare tumor of craniofacial bones in children: a pediatric chondroblastic osteosarcoma case with diagnostic and therapeutic problems. Pediatr Hematol Oncol; 2001 Mar;18(2):147-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare tumor of craniofacial bones in children: a pediatric chondroblastic osteosarcoma case with diagnostic and therapeutic problems.
  • Osteosarcoma of the cranial facial region is uncommon and only rarely involves the ethmoid or sphenoid bones.
  • The authors report on an unusual case of a 17-year-old male presenting with chondroblastic osteosarcoma of the maxillary, ethmoid, and sphenoid sinuses who remains well and disease-free at 46 months.
  • He was treated with anterior craniofacial resection followed by postoperative radiotherapy to the sight of the primary tumor.
  • He did not receive chemotherapy because of emerging hepatitis-B infection and vasculitis.
  • The literature on extragnathic craniofacial osteosarcomas is reviewed with particular emphasis on treatment options of this rare tumor.
  • [MeSH-major] Osteosarcoma / therapy. Skull Neoplasms / therapy
  • [MeSH-minor] Adolescent. Chondrocytes / pathology. Disease-Free Survival. Ethmoid Sinus / pathology. Ethmoid Sinus / surgery. Humans. Magnetic Resonance Imaging. Male. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Maxillary Sinus Neoplasms / therapy. Sphenoid Sinus / pathology. Sphenoid Sinus / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11255734.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Blanco AI, Chao KS, Ozyigit G, Adli M, Thorstad WL, Simpson JR, Spector GJ, Haughey B, Perez CA: Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy. Int J Radiat Oncol Biol Phys; 2004 May 1;59(1):51-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To assess the clinical features, prognostic factors, results, and complications of treatment of carcinomas of the paranasal sinus.
  • METHODS AND MATERIALS: The records of 106 patients (72 men and 34 women) with paranasal sinus carcinoma treated with curative intent at Washington University between January 1960 and August 1998 were analyzed.
  • Most tumors originated in the maxillary (76%) or ethmoid (18%) sinus.
  • All patients underwent radiotherapy (RT), combined with surgery in 65%; 2% received chemotherapy.
  • The 5-year local tumor control, locoregional tumor control, disease-free survival (DFS), and overall survival rate was 58%, 39%, 33%, and 27%, respectively.
  • Nodal status at presentation emerged as a statistically significant predictor for locoregional tumor control and DFS in multivariate analysis.
  • CONCLUSION: This review of a large, single-institution experience of paranasal sinus carcinoma patients who underwent RT showed that locoregional tumor progression and recurrence remain predominant patterns of failure despite aggressive local treatment with combined surgery and RT.
  • DFS improved slightly with combined modality treatment.
  • The overall survival rates remained suboptimal, suggesting a need for more accurate determination of tumor extent, as well as more effective locoregional and systemic therapies.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Ethmoid Sinus. Female. Follow-Up Studies. Humans. Male. Maxillary Sinus Neoplasms / radiotherapy. Middle Aged. Prognosis. Proportional Hazards Models. Radiation Injuries / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15093898.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kumar A, Bentley T: Sinonasal poorly differentiated carcinoma presenting clinically as esthesioneuroblastoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: A 54 year old white male presented with progressive double vision, left nasal congestion, proptosis of left eye and intermittent pain in left eye and frontal sinus region of 7-8 months duration.
  • Intranasal cavity revealed edematous mucosa with soft tissue mass filling mid aspect of nasal cavity on the left.
  • CT scan revealed a large destructive mass involving the left nasal cavity and ethmoid sinus extending into the left orbit with displacement of the globe and destruction of the anterior cranial fossa including the frontal bone.
  • MRI revealed a large sinonasal tumor (5.2x7x7.5cm) extending through the cribriform plate, anteromedial floor of the middle cranial fossa and through the inner and outer table of the frontal bones, more to the left than to the right of midline.
  • He is currently being treated with combined radiation therapy and chemotherapy (carboplatin/paclitaxel).
  • ONB is a rare tumor located in the roof of the nasal cavity and paranasal sinuses.
  • Most patients have locally extensive disease and often, distant metastases at diagnosis.
  • Multimodality approaches (eg, sequential chemotherapy, radiation therapy and craniofacial resection) can cure some patients with localized disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015298.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kartha SS, Bumpous JM: Synovial cell sarcoma: diagnosis, treatment, and outcomes. Laryngoscope; 2002 Nov;112(11):1979-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial cell sarcoma: diagnosis, treatment, and outcomes.
  • OBJECTIVES/HYPOTHESIS: Synovial cell sarcoma is a mesenchymal tumor predominantly of the lower extremities.
  • Our experience has demonstrated aggressive behavior of this neoplasm in the head and neck.
  • METHODS: We obtained the records of patients diagnosed with head and neck synovial sarcoma from the Tumor Registry of the University of Louisville School of Medicine (Louisville, KY) and affiliated hospitals for data compiled between January 1990 and December 2000.
  • Data on patient demographics, clinical findings and symptoms, histological findings, treatment, extent of disease, recurrence, and survival were recorded.
  • All patients received chemotherapy after recurrence.
  • Four of the five patients had local recurrence, and all five of the patients developed distant metastases.
  • Novel sites are reported including the ethmoid sinus and the parotid gland.
  • The aggressive nature of the disease may require modification of accepted treatment modalities and sequence.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12439166.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Knott PD, Gannon FH, Thompson LD: Mesenchymal chondrosarcoma of the sinonasal tract: a clinicopathological study of 13 cases with a review of the literature. Laryngoscope; 2003 May;113(5):783-90
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Mesenchymal chondrosarcoma of the sinonasal tract is a rare, malignant tumor of extraskeletal origin.
  • The maxillary sinus was the most common site of involvement (n = 9), followed by the ethmoid sinuses (n = 7) and the nasal cavity (n = 5).
  • All cases were managed by surgery with adjuvant radiation therapy (n = 4) and/or chemotherapy (n = 3).
  • The overall mean survival was 12.1 years, although five of six patients who developed local recurrences died of disease (mean survival, 6.5 y).
  • CONCLUSIONS: Mesenchymal chondrosarcoma of the sinonasal tract is an aggressive tumor with a predilection for young women.
  • Aggressive, exenterative surgery combined with adjuvant therapy appears to yield the best clinical outcome.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Chondrosarcoma, Mesenchymal / radiography. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / radiography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792311.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


18. Durko M, Murlewska A, Gryczyński M, Ratyńska M, Pietruszewska W: [Angiofibroma of the nasal cavity and anterior ethmoid cells--problems in differential diagnosis]. Otolaryngol Pol; 2007;61(5):736-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiofibroma of the nasal cavity and anterior ethmoid cells--problems in differential diagnosis].
  • It is a relatively rare benign fibrovascular tumor originating in the posterior lateral wall of the nasopharynx with only a very few cases diagnosed in females.
  • CASE REPORT: Authors present a case of a 26 y.o. woman with JNA in left nasal cavity with extension to the anterior left ethmoid cells diagnosed and surgically treated at the ENT Department, Medical University of Lodz.
  • Patient presented in past medical history: lymphoma malignum--abdominal location--surgical treatment and chemotherapy (1986) with no clinical signs of recurrence.
  • Diagnosis based on histopathologic examination with immunochemical staining (vimentin, actin, desmin, S-100 protein).
  • CT of paranasal sinuses in frontal and axial plains--left nasal cavity filled with a solid pathologic tissue.
  • In the left anterior ethmoid cells extension of the tumor could be seen.
  • Surgical treatment--tumor has been surgically resected with no complications.
  • CONCLUSION: Although angiofibroma in females is an extremely rare tumor of a sinonasal tract it should be taken into consideration in the differential diagnosis of all nasal cavity tumors (especially solitary fibrous tumor).
  • It is not possible to make differential diagnosis on physical examination.
  • The only way to confirm the diagnosis is histopathologic examination with immunochemical staining.
  • [MeSH-major] Angiofibroma / pathology. Ethmoid Sinus / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Nasal Cavity / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552009.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


19. Cohen ZR, Marmor E, Fuller GN, DeMonte F: Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus; 2002 May 15;12(5):e3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Olfactory neuroblastoma (ON) is a rare neoplasm arising from the olfactory epithelium and found in the upper nasal cavity.
  • Based on the belief that misdiagnosis commonly occurs, they emphasized the importance of establishing the correct diagnosis, because the treatment regimens and prognosis of these tumor types are often significantly different.
  • Demographic data were collected, physical findings and mode of treatments were documented, and neuroimaging studies were assessed.
  • Only in two of 12 patients was the diagnosis of ON confirmed.
  • Eight of 10 patients in whom lesions were misdiagnosed required significant alteration in the initially proposed treatment plan.
  • The correct diagnosis should be ensured before initiating treatment to provide the optimum therapy and spare the patients from needless and potentially toxic treatment.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Diagnostic Errors. Esthesioneuroblastoma, Olfactory / diagnosis. Melanoma / diagnosis. Nasal Cavity. Nose Neoplasms / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blindness / etiology. Case Management. Cisplatin / administration & dosage. Cisplatin / adverse effects. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Ethmoid Sinus / pathology. Humans. Hypopituitarism / etiology. Iatrogenic Disease. Male. Middle Aged. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / pathology. Radiation Injuries / etiology. Radiotherapy / adverse effects. Retrospective Studies. Sphenoid Sinus / pathology. Vincristine / administration & dosage. Vincristine / adverse effects


20. Lin CY, Chen HH, Chen HH, Fang SY, Tsai ST: Ethmoid sinus cancer: results of treatment with surgery and combined therapy. Acta Otolaryngol; 2004 Dec;124(10):1220-5
Genetic Alliance. consumer health - Sinus cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethmoid sinus cancer: results of treatment with surgery and combined therapy.
  • OBJECTIVE: Ethmoid sinus cancer is a rare paranasal sinus malignancy.
  • Its characteristics include a low incidence rate, a great variety of histopathological types and multiple treatment modalities.
  • The aim of this study was to examine the outcome of a population of Asian patients with advanced ethmoid sinus cancers that had been treated with surgery plus combined therapy.
  • MATERIAL AND METHODS: Between January 1989 and December 2002 inclusive, 19 newly diagnosed patients with ethmoid sinus cancers who had undergone surgical intervention were enrolled, T4 being the principal carcinoma stage (68.4%).
  • All participating cases proved to be node-negative and no evidence of any distant metastasis was detected at the time of diagnosis.
  • The major treatment modality was surgery plus postoperative radiotherapy.
  • RESULTS: The estimated overall and disease-free survival rates 3 years post-treatment were 49.4% and 26.3%, respectively.
  • Local tumor recurrence was more common than regional recurrence and/or distant metastasis.
  • A total of 5/15 T3-T4 patients (33%) developed a neck metastasis, 3 of whom also suffered a distant metastasis.
  • CONCLUSIONS: Ethmoid sinus cancer typically demonstrates a propensity for late diagnosis and poor prognosis.
  • This study confirms that craniofacial resection plus combined associated therapy is the optimal approach for the effective management of extensive ethmoid sinus tumors and is associated with an acceptable morbidity rate.
  • More aggressive disease management featuring prophylactic concurrent chemoradiotherapy including neck or elective neck dissection plus chemotherapy should be considered for T3-T4 patients as opposed to T1-T2 patients.
  • [MeSH-major] Carcinoma / therapy. Ethmoid Sinus. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768822.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


21. Neves MC, Lessa MM, Voegels RL, Butugan O: Primary non-Hodgkin's lymphoma of the frontal sinus: case report and review of the literature. Ear Nose Throat J; 2005 Jan;84(1):47-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the frontal sinus: case report and review of the literature.
  • Most cases of primary non-Hodgkin's lymphoma of the sinonasal tract occur in the maxillary sinus, ethmoid sinus, and nasal cavity; its occurrence in the frontal sinus is extremely rare.
  • We report a case of primary type B non-Hodgkin's lymphoma of the frontal sinus in a 43-year-old man.
  • The patient complained of frontal headaches that had not improved with analgesic drugs, and he presented with a frontal bulge that involved the left upper eyelid; the bulge had progressively enlarged over a 3-month period A biopsy of the mass identified the type B non-Hodgkin's lymphoma.
  • Immunohistochemical study not only confirmed the histologic type of the tumor, it also provided some important information about the primary tumor site.
  • Advances in immunohistochemistry have shown that type B non-Hodgkin's lymphoma is more common in North American and European patients, whereas subtype T is more common in Asians and in some Latin Americans.
  • The treatment of this condition is still controversial, but the combination of radiotherapy and chemotherapy has yielded the best results in all stages of the disease.
  • [MeSH-major] Frontal Sinus. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742775.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


22. Furukido K, Takeno S, Ueda T, Yajin K: Cytokine profile in paranasal effusions in patients with chronic sinusitis using the YAMIK sinus catheter with and without betamethasone. Eur Arch Otorhinolaryngol; 2005 Jan;262(1):50-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine profile in paranasal effusions in patients with chronic sinusitis using the YAMIK sinus catheter with and without betamethasone.
  • Recently, the YAMIK sinus catheter (YAMIK) has been reported to be a useful therapeutic device in the treatment of sinusitis.
  • (1) subjective nasal clinical symptoms (nasal discharge, nasal obstruction, postnasal drip and headache), (2) X-ray photographs (ethmoid and maxillary sinuses) and (3) cytokine levels (IL-1beta, IL-8 and TNF-alpha) by enzyme-linked immunosorbent assay.
  • The total nasal symptom scores significantly decreased after the first therapy, and the total X-ray photograph scores significantly decreased after therapy with either NS or the betamethasone solution.
  • In both NS and betamethasone patients, the levels of IL-1beta and IL-8 had significantly decreased by the 3rd and 2nd weeks after therapy, respectively.
  • In contrast, the TNF-alpha level decreased after the first therapy with betamethasone solution and remained unchanged after therapy with NS.
  • These findings suggest that evacuation of the pathological effusions in sinuses may exert a beneficial effect by reducing the levels of IL-1beta and IL-8, and we speculate that removal of pathological effusions from the sinuses may provide treatment through different mechanisms than those that occur in treatment with betamethasone.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Betamethasone / therapeutic use. Interleukin-1 / immunology. Interleukin-8 / immunology. Sinusitis / drug therapy. Sinusitis / immunology. Tumor Necrosis Factor-alpha / immunology

  • MedlinePlus Health Information. consumer health - Sinusitis.
  • Hazardous Substances Data Bank. BETAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Rhinol. 2000 Nov-Dec;14(6):367-73 [11197112.001]
  • [Cites] Clin Exp Allergy. 1998 Sep;28(9):1145-52 [9761019.001]
  • [Cites] Am J Otolaryngol. 1999 May-Jun;20(3):143-50 [10326748.001]
  • [Cites] J Allergy Clin Immunol. 1996 Sep;98(3):659-70 [8828544.001]
  • [Cites] Auris Nasus Larynx. 2000 Oct;27(4):343-7 [10996494.001]
  • [Cites] J Laryngol Otol. 1996 Oct;110(10):926-8 [8977854.001]
  • [Cites] J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):395-400 [10069871.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1985 Apr;10(2):79-83 [4028471.001]
  • [Cites] Acta Otolaryngol. 1992 Sep;112(5):882-9 [1456045.001]
  • [Cites] Allergy. 1999 Jul;54(7):691-9 [10442524.001]
  • [Cites] Rhinology. 1996 Jun;34(2):123-4 [8876077.001]
  • [Cites] Allergy. 2001 Apr;56(4):333-8 [11284802.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1827-30 [12368623.001]
  • [Cites] Laryngoscope. 2000 Aug;110(8):1271-6 [10942125.001]
  • [Cites] Auris Nasus Larynx. 2000 Jan;27(1):51-8 [10648069.001]
  • [Cites] Otolaryngol Head Neck Surg. 1997 Sep;117(3 Pt 2):S1-7 [9334782.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):98-102 [7793513.001]
  • [Cites] J Allergy Clin Immunol. 2000 Aug;106(2):213-27 [10932063.001]
  • (PMID = 14963719.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Interleukin-1; 0 / Interleukin-8; 0 / Tumor Necrosis Factor-alpha; 9842X06Q6M / Betamethasone
  •  go-up   go-down


23. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • The most common site of tumor origin was the nasal cavity (52%), followed by the ethmoid sinuses (28%).
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-major] Endoscopy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Koch M, Blatterspiel GJ, Niedobitek G, Constantinidis J: [Angiocentric T/NK cell lymphoma: a special clinical-pathological entity of lethal midline granuloma. A case report]. Laryngorhinootologie; 2001 Jul;80(7):410-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Das angiozentrische T/NK-Zell-Lymphom--eine spezielle klinisch-pathologische Entität des letalen Mittelliniengranulomes: eine Fallbeschreibung.
  • After exclusion of granulomatous infections, rare granulomatous diseases and epithelial neoplasias, the differential diagnosis includes the following entities: Wegener's granulomatosis (WG), malignant lymphoma and idiopathic midline destructive disease (IMDD).
  • PATIENT: A case of a 35-year-old male patient with an angiocentric nasal T/NK-cell lymphoma, which involved the left lacrimal cyst, the left maxillar and ethmoid sinus as well as the soft and hard palates, is presented.
  • The patient underwent sinus surgery for pansinusitis three times.
  • After development of midline destructive disease the diagnosis of angiocentric lymphoma was established.
  • RESULTS: Soon after the diagnosis a combination high-dose radiochemotherapy was performed.
  • CONCLUSIONS: Because of its poor prognosis the angiocentric nasal NK/T-cell lymphoma should included early into the differential diagnosis of the midline granuloma syndrome.
  • Correct biopsy technic and in situ hybridization of EBV can be important for an early diagnosis.
  • Therapy should be aggressive and consists of high-dose radiotherapy, which is most important to reach local tumor control, and combination chemotherapy, the use of which is presently in discussion.
  • [MeSH-major] Granuloma, Lethal Midline / diagnosis. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Nose Neoplasms / diagnosis. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Prognosis. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Midline lethal granuloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11488153.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Diba R, Saadati H, Esmaeli B: Outcomes of dacryocystorhinostomy in patients with head and neck tumors. Head Neck; 2005 Jan;27(1):72-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The tumor diagnoses were squamous cell carcinoma (n = 18), chondrosarcoma (n = 3), sinonasal carcinoma (n = 2), adenoid cystic carcinoma (n = 2), sinonasal papilloma (n = 2), esthesioneuroblastoma (n = 1); hemangiopericytoma (n = 1); ameloblastoma (n = 1), and osteosarcoma (n = 1).
  • Twenty-eight patients had a maxillectomy or other sinus surgeries, 10 had radiotherapy, and 14 had chemotherapy and radiotherapy before DCR.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Ethmoid Bone / surgery. Female. Humans. Male. Maxilla / surgery. Middle Aged. Paranasal Sinuses / surgery. Radiotherapy, Adjuvant. Recurrence. Retrospective Studies. Sphenoid Bone / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 15565560.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Paiva MB, Bublik M, Castro DJ, Udewitz M, Wang MB, Kowalski LP, Sercarz J: Intratumor injections of cisplatin and laser thermal therapy for palliative treatment of recurrent cancer. Photomed Laser Surg; 2005 Dec;23(6):531-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumor injections of cisplatin and laser thermal therapy for palliative treatment of recurrent cancer.
  • OBJECTIVE: The aim of this work was to report initial findings on the clinical application of intratumor injection of cisplatin in a gel (CDDP/gel) combined with laser-induced thermal therapy (LITT) for cancer treatment in a single patient with advanced stage disease.
  • BACKGROUND DATA: LITT with the neodymium:yttriumaluminum- garnet (Nd:YAG) laser via fiberoptics is a precise, minimally invasive alternative for thermoablation of unresectable or recurrent head and neck neoplasms, but recurrence is often seen at the treatment margins.
  • Combining intratumor chemotherapy with interstitial laser should be most effective using drugs with thermally enhanced toxicity, such as cisplatin.
  • The CDDP/gel therapeutic implant was expected to retain a higher concentration of cisplatin in the tumor margins for improved LITT treatment of the patient presented.
  • METHODS: In this case report, the cisplatin dose was 0.25 mL gel/cm(3) tumor volume (20 mg of CDDP) followed by LITT (Nd:YAG laser, 50 W, PD = 2,200 J/cm(2)) after the chemotherapy session.
  • RESULTS: The patient responded with local tumor eradication, and no signs of systemic toxicity were observed related to this therapy.
  • However, the patient developed progressive metastatic disease in the lungs and died 2.5 months later.
  • CONCLUSIONS: This is a report of a patient with an accessible solid tumor who was treated with intratumor injection of CDDP/gel followed by LITT, which proved to be feasible.
  • Based on preclinical evidence obtained at UCLA and the results of this study, we are encouraged to continue our refinement of LITT combined with chemotherapy for cancer treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Laser Therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Aged. Ethmoid Sinus. Female. Fiber Optic Technology. Humans. Injections, Intralesional. Melanoma / therapy. Palliative Care. Paranasal Sinus Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356142.001).
  • [ISSN] 1549-5418
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA 88921
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Esposito F, Kelly DF, Vinters HV, DeSalles AA, Sercarz J, Gorgulhos AA: Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies. J Neurooncol; 2006 Feb;76(3):299-306
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies.
  • BACKGROUND: Primary neoplasms of the sphenoid sinus are a rare occurrence, accounting for approximately 1-2% of all paranasal sinus tumors.
  • METHODS: Four patients with sphenoid sinus neoplasms were identified (1%), all treated during the year 2003.
  • MRIs in all patients demonstrated large sphenoid sinus masses with partial clival and sellar bone erosion but with clear visualization of the pituitary gland above the mass.
  • Cavernous sinus invasion was present in all four cases, including one patient with tumor in the ethmoid sinus and intra-tumoral hemorrhage.
  • All patients underwent subtotal tumor removal via an endonasal transsphenoidal route.
  • Tumor histology included neuroendocrine carcinoma, sinonasal undifferentiated carcinoma, mucoepidermoid carcinoma, and giant cell tumor.
  • Metastatic work-ups were negative in all patients, and all received fractionated stereotactic radiotherapy; three received chemotherapy.
  • One patient required a second endonasal tumor debulking 15 months after the first for new visual loss that then resolved.
  • In this small series, they presented with cavernous sinus symptoms and headache but not endocrinopathy.
  • Their aggressive nature warrants a multimodality treatment plan including surgical debulking, radiotherapy, and chemotherapy in some cases.
  • [MeSH-major] Neurosurgical Procedures. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy. Sphenoid Sinus / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma / therapy. Carcinoma, Giant Cell / metabolism. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / therapy. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2002 Sep;51(3):699-705; discussion 705-7 [12188948.001]
  • [Cites] Head Neck Surg. 1984 Jan-Feb;6(3):761-76 [6319335.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Laryngoscope. 1989 Jul;99(7 Pt 1):716-20 [2747395.001]
  • [Cites] Laryngoscope. 1963 May;73:537-46 [14011951.001]
  • [Cites] Cephalalgia. 1988 Dec;8(4):229-36 [3219724.001]
  • [Cites] Laryngoscope. 1997 Dec;107(12 Pt 1):1590-5 [9396670.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14 (1):11-22 [3335447.001]
  • [Cites] Yonsei Med J. 1988;29(3):209-18 [3057747.001]
  • [Cites] Head Neck. 1996 Mar-Apr;18(2):160-5; discussion 166 [8647682.001]
  • [Cites] Neurosurgery. 1993 Oct;33(4):602-8; discussion 608-9 [8232799.001]
  • [Cites] J Neurosurg. 1981 Aug;55(2):187-93 [7252541.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Laryngoscope. 1973 Aug;83(8):1252-65 [4758128.001]
  • [Cites] Pituitary. 2002;5(4):261-5 [14558675.001]
  • [Cites] World J Surg. 2003 Jul;27(7):849-55 [14509518.001]
  • [Cites] Minim Invasive Neurosurg. 1998 Jun;41(2):66-73 [9651913.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):663-72 [12152781.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):581-9 [1503031.001]
  • [Cites] J Otolaryngol. 1978 Oct;7(5):379-88 [105151.001]
  • [Cites] Arch Otolaryngol. 1978 Oct;104(10):585-7 [697636.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):765-8 [8663951.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1084-91; discussion 1091-2 [10807240.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Jun;102(6):709-16 [2115658.001]
  • [Cites] Eur J Pediatr. 1996 Aug;155(8):717-9 [8839732.001]
  • [Cites] J Otolaryngol. 1990 Apr;19(2):122-9 [2348505.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Head Neck. 1991 May-Jun;13(3):208-12 [2037472.001]
  • [Cites] Med J Aust. 2000 Nov 20;173(10):548-9 [11194741.001]
  • [Cites] Neuroradiology. 1998 Oct;40(10 ):651-5 [9833894.001]
  • [Cites] Brain. 1984 Sep;107 ( Pt 3):855-70 [6478180.001]
  • [Cites] J Craniofac Surg. 1995 Jan;6(1):15-23 [8601000.001]
  • [Cites] J Neurosurg Sci. 1999 Mar;43(1):25-36 [10494663.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Br J Neurosurg. 1994;8(1):51-5 [8011194.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 May;259(5):266-8 [12107531.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):350-8 [12593622.001]
  • [Cites] Pathology (Phila). 1996;3(2):513-34 [8795833.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Jan;120(1):19-25 [8274251.001]
  • [Cites] Am J Emerg Med. 2001 Jan;19(1):88-90 [11146033.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):913-5; discussion 915-6 [9574657.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):367-72 [12598339.001]
  • [Cites] Neurosurgery. 2003 Nov;53(5):1126-35; discussion 1135-7 [14580279.001]
  • [Cites] Cancer. 1977 Dec;40(6):3038-41 [412586.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] J Laryngol Otol. 1995 Oct;109(10):951-5 [7499947.001]
  • (PMID = 16163447.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Hallacq P, Labrousse F, Roullet B, Orsel S, Bessede JP, Moreau JJ: [Adenoid cystic carcinomas invading the skull base. Apropos of 4 cases and review of the literature]. Neurochirurgie; 2001 Dec;47(6):542-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinomes adénoïdes kystiques envahissant la base du crâne. A propos de 4 observations et revue de la littérature.
  • Neurosurgical decision making is not well defined regarding the extent of intracranial tumor component removal, as neurosurgical expertise is limited for this peculiar type of tumors.
  • Over a 13-year period, four adenoid cystic carcinomas invading the skull base were operated on at our institution: two tumors originated in the parotid gland, one in the sphenoid sinus, and one in the ethmoid sinus.
  • One patient with advanced metastatic disease was submitted to chemotherapy.
  • Three patients died from local tumor progression and distant metastases within three years after the intracranial tumor extension has been diagnosed.
  • The patient with an ethmoid tumor is still alive seven years after surgery without any evidence of local tumor progression nor distant metastases.
  • Surgery remains the gold standard treatment for adenoid cystic carcinomas invading the skull base.
  • However, in our opinion a large tumor removal, without or with bone osteotomies, but without sacrifice of cranial nerves, cavernous sinus, internal carotid artery, and of the orbit allows patient survival with an acceptable comfort and absence of psychological distress due to disfigurating surgery nor surgically induced neurological functional deficit.
  • The place of chemotherapy has, yet, to be determined.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Ethmoid Sinus / surgery. Paranasal Sinus Neoplasms / surgery. Parotid Neoplasms / surgery. Skull Base Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915613.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Yamamoto R, Hosokawa S, Yamatodani T, Morita S, Okamura J, Mineta H: [Eight cases of neuroendcrine carcinoma of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):517-22
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small cell neuroendocrine carcinoma of the head and neck is rare, and diagnosis may be difficult.
  • Three cases arose from the maxillary sinus, two from the ethmoid sinus, one from the parotid gland, one from the tonsil, and one from the larynx.
  • Histological analysis by hematoxylin-eosin staining tentatively revealed malignant lymphoma and undifferentiated carcinoma in two cases each, while immunohistological and/or electron microscopy analysis confirmed histological diagnosis.
  • All were treated by chemotherapy (VP-16, CDDP) and seven cases with radiotherapy based on the schedule of small cell carcinoma of the lung and two cases with lesional resection.
  • Chemotherapy and radiotherapy were effective locally.
  • Long-term survival thus requires the effective treatment of distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Epirubicin / administration & dosage. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697475.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; PE regimen
  •  go-up   go-down


30. Uchida D, Shirato H, Onimaru R, Endou H, Aoyama H, Tsuchiya K, Nishioka T, Homma A, Furuta Y, Fukuda S, Miyasaka K: Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery. Cancer J; 2005 Mar-Apr;11(2):152-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery.
  • PURPOSE: Ethmoidal malignant tumors, for which intensity-modulated radiotherapy is expected to improve outcome, consist of heterogeneous pathological types.
  • We investigated the long-term treatment outcome of squamous cell carcinoma and undifferentiated carcinoma of the ethmoid sinus.
  • Radiation dose varied from 50.4 Gy in 16 fractions (50.4 Gy/16 Fr) to 65 Gy in 26 fractions with or without stereotactic boost irradiation.
  • Eleven patients received chemotherapy consisting mainly of platinum-based compounds.
  • Visual acuity of a single eye was impaired in three patients and was lost in five patients as a result of tumor progression, but no patient had visual impairment or loss due to radiotherapy.
  • CONCLUSION: Ethmoid squamous cell carcinoma or undifferentiated carcinoma was diagnosed at advanced T stages and was treated with radiotherapy; these patients had a poorer outcome than patients with adenocarcinoma or adenoid cystic carcinoma.
  • Prospective trials using advanced technology should be carefully compared with historical controls because pathological types can considerably influence the treatment results.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Ethmoid Sinus / pathology. Paranasal Sinus Neoplasms / radiotherapy. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15969991.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Chen AM, Daly ME, El-Sayed I, Garcia J, Lee NY, Bucci MK, Kaplan MJ: Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):338-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary tumor sites included the nasal cavity (11 patients), maxillary sinus (5 patients), and ethmoid sinus (5 patients).
  • Local-regional treatment included surgery followed by postoperative radiotherapy (PORT) with or without adjuvant chemotherapy for 17 patients; neoadjuvant chemoradiotherapy followed by surgery for 2 patients; and definitive chemoradiotherapy for 2 patients.
  • There was no difference in local control according to initial treatment approach, but among the 19 patients who underwent surgery the 5-year local control rate was 74% for those with gross tumor resection, compared with 24% for those with subtotal tumor resection (p = 0.001).
  • CONCLUSION: The suboptimal outcomes suggest a need for more effective therapies.
  • Gross total resection should be the goal of all treatments whenever possible.
  • [MeSH-major] Carcinoma / therapy. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Combined Modality Therapy / methods. Ethmoid Sinus. Female. Follow-Up Studies. Humans. Male. Maxillary Sinus Neoplasms / mortality. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / therapy. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local. Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Adjuvant / methods. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207030.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Lu TX, Mai WY, Teh BS, Zhao C, Han F, Huang Y, Deng XW, Lu LX, Huang SM, Zeng ZF, Lin CG, Lu HH, Chiu JK, Carpenter LS, Grant WH 3rd, Woo SY, Cui NJ, Butler EB: Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2004 Mar 1;58(3):682-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report our initial experience on the feasibility, toxicity, and tumor control using intensity-modulated radiotherapy (IMRT) for retreatment of recurrent nasopharyngeal carcinoma (NPC).
  • The average time to the nasopharyngeal recurrence was 30.2 months after initial conventional RT.
  • The median isocenter dose to the nasopharynx was 70 Gy (range 60.9-78.0) for the initial conventional RT.
  • All patients were restaged at the time of recurrence according to the 1992 Fuzhou, China staging system on NPC.
  • Invasion of the nasal cavity, maxillary sinus, ethmoid sinus, sphenoid sinus, and cavernous sinus and erosion of the base of the skull was found in 8, 1, 3, 8, 15, and 20 patients, respectively.
  • The gross tumor volume (GTV) was contoured according to the International Commission on Radiation Units and Measurements (ICRU) Report 62 guidelines.
  • The GTV in the nasopharynx and positive lymph nodes in the neck received a prescription dose of 68-70 Gy and 60 Gy, respectively.
  • Three patients who had positive lymph nodes were treated with five to six courses of chemotherapy (cisplatin + 5-fluorouracil) after IMRT.
  • RESULTS: The treatment plans showed that the percentage of GTV receiving 95% of the prescribed dose (V(95-GTV)) was 98.5%, and the dose encompassing 95% of GTV (D(95-GTV)) was 68.1 Gy in the nasopharynx.
  • The mean dose to the GTV was 71.4 Gy.
  • Three patients developed metastases at a distant site: two in the bone and one in the liver and lung at 13 months follow-up.
  • Acute toxicity (skin, mucosa, and xerostomia) was acceptable according to the Radiation Therapy Oncology Group criteria.
  • Tumor necrosis was seen toward the end of IMRT in 14 patients (28.6%).
  • CONCLUSION: The improvement in tumor target coverage and significant sparing of adjacent critical structures allow the feasibility of IMRT as a retreatment option for recurrent NPC after initial conventional RT.
  • The treatment-related toxicity profile was acceptable.
  • The initial tumor response/local control was also very encouraging.
  • In contrast to primary NPC, recurrent NPC reirradiated with high-dose IMRT led to the shedding of tumor necrotic tissue toward the end of RT.
  • More patients and longer term follow-up are warranted to evaluate late toxicity and treatment outcome.
  • [MeSH-major] Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14967420.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Windfuhr JP, Remmert S: [Extranasopharyngeal angiofibroma of the nasal cavity and paranasal sinuses]. Laryngorhinootologie; 2004 May;83(5):308-16
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis is widely based on radiographic imaging to avoid ill-advised biopsy which may result in brisk bleeding.
  • This study was undertaken to evaluate the incidence, clinical features and complications that may occur during the process of diagnosis and surgical therapy of angiofibromas outside the nasopharynx.
  • RESULTS: Our patient received multi-agent chemotherapy elsewhere due to a misdiagnosed angiofibroma.
  • Computed Tomography (CT) revealed a maxillary tumor which was repeatedly biopsied.
  • The maxilla was most commonly affected (38 %), less frequently the ethmoid, nasal cavity or septum, beside others.
  • In 38 patients, symptoms developed within 12 months or less (average: 8.5 months).
  • Brisk bleeding occurred in 10 patients during tumor removal and resulted from biopsies in 11 of 20 patients.
  • CONCLUSION: Extranasopharyngeal angiofibromas of the nasal cavity or paranasal sinuses should be included in the differential diagnosis of nasal tumors.
  • Signs of questionable hypervascularity in Computed Tomography and Magnetic Resonance Imaging (MRI) should indicate arteriography prior to surgical procedures.
  • Preoperative embolization of hypervascular lesions during arteriography will reduce the risk of brisk bleeding during biopsy or surgical tumor removal.
  • [MeSH-major] Angiofibroma / diagnosis. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Angiography. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Male. Maxillary Sinus Neoplasms / diagnosis. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / surgery. Middle Aged. Nasal Cavity / pathology. Nasal Cavity / surgery. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15143448.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 89
  •  go-up   go-down


34. Padovani L, Pommier P, Clippe S S, Martel-Lafay I, Malet C, Poupart M, Zrounba P, Ceruse P, Desmes S, Carrie C, Montbarbon X, Ginestet C: Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients. Int J Radiat Oncol Biol Phys; 2003 May 1;56(1):169-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients.
  • PURPOSE: To assess local control, survival, and clinical and dosimetric prognostic factors in 25 patients with locally advanced maxillary or ethmoid sinus carcinoma treated by three-dimensional conformal radiotherapy (RT).
  • Seven patients received chemotherapy (concomitant with RT in four).
  • The following quality indexes were defined for the 95% and 90% isodoses: tumor conformity index, normal tissue conformity index, and global conformity index.
  • RESULTS: The median radiation dose to the planned treatment volume was 63 Gy, with a minimal dose of 60 Gy, except in 2 patients whose cancer progressed during RT.
  • After a median follow-up of 25 months, 14 local tumor recurrences developed.
  • The radiation dose and tumor conformity index value were not significant prognostic indicators.
  • Two patients died of acute infectious toxicity, and two developed late ipsilateral ocular toxicity.
  • [MeSH-major] Carcinoma / radiotherapy. Imaging, Three-Dimensional. Paranasal Sinus Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Ethmoid Sinus. Eye Injuries / etiology. Eye Injuries / prevention & control. Female. Follow-Up Studies. Humans. Life Tables. Male. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / mortality. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Optic Nerve Injuries / etiology. Optic Nerve Injuries / prevention & control. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694835.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD: A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am J Clin Oncol; 2008 Oct;31(5):413-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor evaluation by radiographic and physical examination was performed after every 3 cycles using Response Evaluation Criteria in Solid Tumors.
  • Three patients with colon cancer, 1 patient with renal cell cancer and 1 patient with adenosquamous cell carcinoma of the ethmoid sinus had stable disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Disease-Free Survival. Epirubicin / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838875.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement